Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Abbott 2Q | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Abbott 2Q

Humira sales continue to drive pharma growth

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Abbott 2Q

2Q Revenues: $9.6 billion (+9%)

2Q Earnings: $1.9 billion (+50%)

YTD Revenues: $18.7 billion (+13%)

YTD Earnings: $2.8 billion (+22%)

Comments: Growth in the quarter was driven by a 13% increase in Pharmaceutical sales. Humira sales approached $2.0 billion in the quarter, up 25%. TRILIPIX/TriCor sales were $419 million, up 6%. Kaletra sales were up 14% to $336 million. Niaspan sales were up 17% to $247 million. Lupron sales were up 9% to $205 million. Pediatric Nutritionals accounted for $779 million (+2%) of sales in the quarter and Coronary Stents accounted for $525 million (-2%).

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters